The potential for Treg-enhancing therapies in tissue, in particular skeletal muscle, regeneration

Author:

Hanna Bola S1,Yaghi Omar K1,Langston P Kent1ORCID,Mathis Diane1ORCID

Affiliation:

1. Department of Immunology, Harvard Medical School and Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women’s Hospital ; Boston , USA

Abstract

Summary Foxp3+CD4+ regulatory T cells (Tregs) are famous for their role in maintaining immunological tolerance. With their distinct transcriptomes, growth-factor dependencies and T-cell receptor (TCR) repertoires, Tregs in nonlymphoid tissues, termed “tissue-Tregs,” also perform a variety of functions to help assure tissue homeostasis. For example, they are important for tissue repair and regeneration after various types of injury, both acute and chronic. They exert this influence by controlling both the inflammatory tenor and the dynamics of the parenchymal progenitor-cell pool in injured tissues, thereby promoting efficient repair and limiting fibrosis. Thus, tissue-Tregs are seemingly attractive targets for immunotherapy in the context of tissue regeneration, offering several advantages over existing therapies. Using skeletal muscle as a model system, we discuss the existing literature on Tregs’ role in tissue regeneration in acute and chronic injuries, and various approaches for their therapeutic modulation in such contexts, including exercise as a natural Treg modulator.

Funder

National Institutes of Health

JPB Foundation

Publisher

Oxford University Press (OUP)

Subject

Immunology,Immunology and Allergy

Reference142 articles.

1. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells;Fontenot;Nat Immunol,2003

2. Control of regulatory T cell development by the transcription factor Foxp3;Hori;Science,2003

3. An essential role for Scurfin in CD4+CD25+ T regulatory cells;Khattri;Nat Immunol,2003

4. Regulatory T cells: differentiation and function;Plitas;Cancer Immunol Res,2016

5. Next-generation regulatory T cell therapy;Ferreira;Nat Rev Drug Discov,2019

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3